We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Detects Cancer in Blood Samples In 10 Minutes

By LabMedica International staff writers
Posted on 30 Oct 2025

Detecting cancer recurrence or spread often depends on identifying rare tumor cells circulating in the bloodstream — a process known as a liquid biopsy. More...

However, current methods rely on trained specialists spending hours combing through images of millions of blood cells to find a few abnormal ones. Researchers have now developed an artificial intelligence (AI) algorithm that automates this painstaking task, enabling the detection of cancer cells in approximately ten minutes with unprecedented speed and accuracy.

The new algorithm, called RED (Rare Event Detection), was developed by scientists from the USC Viterbi School of Engineering (Los Angeles, CA, USA) and the USC Dornsife College of Letters, Arts and Sciences (Los Angeles, CA, USA). Unlike existing liquid biopsy systems that rely on human review or predefined cellular features, RED uses deep learning to autonomously detect “outlier” cells that differ from millions of normal blood cells. It does not need prior knowledge of what a cancer cell looks like.

Instead, it identifies unusual cellular patterns and ranks them by rarity, automatically flagging potential cancer cells for further review. In laboratory tests, the researchers evaluated RED using two datasets: blood samples from patients with advanced breast cancer and simulated samples where cancer cells were added to normal blood. The findings, published in Precision Oncology, show that the algorithm achieved a 99% detection rate for epithelial cancer cells and 97% for endothelial cells, while reducing the data volume for human review by a factor of 1,000.

Compared to traditional methods, RED identified twice as many relevant cells associated with cancer, highlighting its ability to eliminate human bias and uncover subtle biological signals. By combining computational modeling with human expertise, the USC team has built a framework that accelerates the analysis of liquid biopsies and supports ongoing cancer monitoring. The approach is already being applied to study outcomes for breast, pancreatic, and multiple myeloma cancers. RED’s ability to detect rare cancer cells in blood samples could also enhance patient surveillance, enabling earlier detection of recurrence and more effective treatment planning.

“This is one of the really great examples where modern AI is really changing the way we do healthcare research,” said Peter Kuhn, University Professor and Director of the Convergent Science Institute in Cancer at USC. “Our next step is to continue pushing the forefront of AI to radically change our ability to find cancer in the blood of patients early.”

Related Links:
USC Viterbi School of Engineering
USC Dornsife College of Letters, Arts and Sciences


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
ESR Analyzer
TEST1 2.0
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.